Jung Choi - Sep 1, 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Chief Business and Strategy Officer
Signature
/s/ Miguel Carrillo, as Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Sep 1, 2021
Transactions value $
-$37,773
Form type
4
Date filed
9/3/2021, 08:01 PM
Previous filing
Sep 24, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Award $3.12K +128 +0.07% $24.39 182K Aug 31, 2021 Direct F1
transaction GBT Common Stock Options Exercise +2.76K +1.51% 185K Sep 1, 2021 Direct F2
transaction GBT Common Stock Tax liability -$40.9K -1.37K -0.74% $29.85 184K Sep 1, 2021 Direct F3
holding GBT Common Stock 25K Sep 1, 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -2.76K -12.5% $0.00 19.3K Sep 1, 2021 Common Stock 2.76K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F3 Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,762 shares of Common Stock underlying the Reporting Person's RSUs.
F4 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Chief Business and Strategy Officer